Description: OKYO Pharma Limited operates as a life sciences and biotechnology company in the United Kingdom. Its development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM-8, a non-opiod analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.
Home Page: www.okyopharma.com
OKYO Technical Analysis
55 Park Lane
London,
W1K 1NA
United Kingdom
Phone:
44 20 7495 2379
Officers
| Name | Title |
|---|---|
| Dr. Gary S. Jacob Ph.D. | CEO & Exec. Director |
| Mr. Michael Paul Beck | Founder |
| Ms. Keeren Shah | Chief Financial Officer |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 15.6883 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 7 |